Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

BACKGROUND: Median overall survival for patients with metastatic soft tissue sarcoma is 12 to 16 months. Olaratumab is a human anti–platelet-derived growth factor receptor α monoclonal antibody which has antitumour activity in human sarcoma xenografts. METHODS: We conducted an open-label phase 1b, r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet
Autors principals: Tap, William D., Jones, Robin L., Van Tine, Brian A., Chmielowski, Bartosz, Elias, Anthony D., Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M., Livingston, Michael B., Pennock, Gregory, Hameed, Meera R., Shah, Gaurav D., Qin, Amy, Shahir, Ashwin, Cronier, Damien M., Ilaria, Robert, Conti, Ilaria, Cosaert, Jan, Schwartz, Gary K.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647653/
https://ncbi.nlm.nih.gov/pubmed/27291997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)30587-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars